Articles and Blogs

FDA

Today in Washington – March 22, 2020: COVID-19 Updates

[03/22/20]

Posted on March 22, 2020 in COVID-19 Daily Updates

Published by: Hall Render

Sunday, March 22 Recap Note – ​We believe this is the most up-to-date information available at this time, but it is subject to change ​as circumstances warrant. Also, all finalized resources can be found ​on the COVID-19 ​Resource ​Center page ​of Hall Render’s website.​ Congressional Outlook A procedural vote to end debate and move to a... READ MORE

Tags: , , , , ,

Today in Washington – March 21, 2020: COVID-19 Updates

[03/21/20]

Posted on March 21, 2020 in COVID-19 Daily Updates

Published by: Hall Render

Saturday, March 21 Recap Note – ​We believe this is the most up-to-date information available at this time, but it is subject to change ​as circumstances warrant. Also, all finalized resources can be found ​on the COVID-19 ​Resource ​Center page ​of Hall Render’s website.​ Congressional Outlook After 12 hours of negotiation on Friday, Republicans and Democrats... READ MORE

Tags: , , , , , , ,

Today in Washington – March 19, 2020: COVID-19 Updates

[03/19/20]

Posted on March 19, 2020 in COVID-19 Daily Updates, Health Law News

Published by: Hall Render

Thursday, March 19 Recap Note – ​We believe this is the most up-to-date information available at this time, but it is subject to change ​as circumstances warrant. Also, all finalized resources can be found ​on the COVID-19 ​Resource ​Center page ​of Hall Render’s website. Congressional Outlook Senate Republicans released the attached proposal for the third COVID-19... READ MORE

Tags: , , , , ,

FDA Issues Guidance on COVID-19 Disruptions to Clinical Trials

[03/19/20]

Posted on March 19, 2020 in Health Law News

Published by: Hall Render

On March 18, 2020, the FDA issued FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic that provides guidance for Sponsors, Clinical Investigators and Institutional Review Boards (“IRBs”) on how to address disruptions in the conduct of clinical trials (“Trials”) as a result of COVID-19. COVID-19 Disruptions to Clinical Trials... READ MORE

Tags: , , , , ,

Today in Washington – March 18, 2020: COVID-19 Updates

[03/18/20]

Posted on March 18, 2020 in COVID-19 Daily Updates, Health Law News

Published by: Hall Render

Wednesday, March 18 Update Note – ​We believe this is the most up-to-date information available at this time, but it is subject to change ​as circumstances warrant. Also, all finalized resources can be found ​on the COVID-19 ​Resource ​Center page ​of Hall Render’s website. Congressional Outlook Sen. Mitch McConnell (R-KY) reversed course and the Senate passed... READ MORE

Tags: , , , , ,

FDA Revisits Unsubstantiated Claims Surrounding Pharmacogenetic Testing

[02/26/20]

Posted on February 26, 2020 in Health Law News

Published by: Hall Render

Pharmacogenetic Testing and the FDA’s 2018 Warning The advent of direct-to-consumer genetic testing has yielded an explosion in the development of various types of genetic tests for clinical treatment and diagnostic purposes. These tests include pharmacogenetic tests, which are used to better understand the role genetics play in an individual patient’s reaction to certain... READ MORE

Tags: , , , ,

Novel Coronavirus 2019-nCoV and FDA’s Emergency Use Authorization Authority

[02/26/20]

Posted on February 26, 2020 in Health Law News

Published by: Hall Render

It is no secret why the novel coronavirus (“2019-nCoV”) outbreak in Wuhan City, Hubei Province, China quickly raised health concerns on an international scale. The coronavirus family contains member viruses with a similarly sinister and deadly past; viruses that seemingly appeared out of nowhere and rapidly spread. For example, two betacoronaviruses were the culprits... READ MORE

Tags: , , , , , , ,

USDA Hemp Producer License – Do the Opportunities Outweigh the Risks?

[01/27/20]

Posted on January 27, 2020 in HR Insights for Health Care

Published by: Hall Render

The USDA Hemp Producer License Rule and Framework On October 31, 2019, the United States Department of Agriculture (“USDA”) published an interim final rule[1] with request for comments in the Federal Register regarding hemp production (“USDA Hemp Rule” or the “Interim Final Rule”).[2] The USDA Hemp Rule establishes a federal hemp producer license and... READ MORE

Tags: , , , , , , ,

Homeopathic Products Manufacturers Beware – FDA Steps Up Plans for New Enforcement Regime

[10/25/19]

Posted on October 25, 2019 in Health Law News

Published by: Hall Render

The centuries-old practice of homeopathic medicine, which has been the subject of much controversy and debate for nearly the entire length of its existence, may finally be going to the mat with the Food & Drug Administration (“FDA”). Amidst growth in the homeopathic products industry and associated concerns with their safety, efficacy and quality,... READ MORE

Tags: , , , ,

What’s in YOUR Cannabidiol Product Claim? FDA and FTC Want to Know

[10/24/19]

Posted on October 24, 2019 in Health Law News

Published by: Hall Render

It isn’t only the U.S. Food & Drug Administration (“FDA”) and Drug Enforcement Agency (“DEA”) that are interested in all things cannabis. Today, the FDA followed earlier warning letters[1] by posting yet another press release regarding an October 10, 2019 warning letter that was issued jointly by the FDA and the Federal Trade Commission... READ MORE

Tags: , , , , ,